Guttorm Raknes, Lars Småbrekke
The results of this study suggest that persistent LDN use leads to reduced dispensing of several medicines used in rheumatoid and seropositive arthritis, possibly due to therapeutic effects. Randomised clinical trials should be performed to investigate whether LDN has a place in the treatment of rheumatic disease, either as an alternative or as an add-on to established pharmacotherapy. The expired patent on naltrexone makes commercial studies unlikely, but the low cost and LDNs outstanding safety profile make it an attractive candidate for both patients and those who pay for health services.
2 replies on “Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study”
When I initially commented I clicked the “Notify me when new comments are added” checkbox and now each time a
comment is added I get four e-mails with the same comment.
Is there any way you can remove me from that service? Thanks!
Thanks in favor of sharing such a pleasant thinking, article is fastidious, thats why i have
read it entirely